SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is facing intense volatility as traders react to the cyclical nature of its heavy concentration in South Korean semiconductor giants like Samsung and SK Hynix. The community is actively debating whether the stock's recent aggressive price swings represent a sustainable bull cycle fueled by AI-driven memory chip shortages or a risky, over-leveraged trade prone to rapid technical corrections.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently under pressure following media reports that it may be exploring a significant equity raise to support its massive AI infrastructure and data center capital expenditure requirements. Investors are debating whether this potential dilution signifies a long-term strategic commitment to AI dominance or a sign of unsustainable spending, leaving the stock caught between concerns over shareholder impact and its core advertising business performance.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

The ProShares Bitcoin Strategy ETF is trending as investors grapple with its ongoing price volatility alongside broader market fluctuations in Bitcoin. Community discussion is heavily focused on the contrast between the ETF's consistent monthly dividend payouts and the NAV decay, with many debating whether to hold for income or shift into spot Bitcoin products.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing extreme downward pressure, with community members expressing panic and frustration as the token hits multi-year lows. Many investors are debating whether these levels represent a rare buying opportunity or a signal of deeper structural failure, with sentiment largely split between those aggressively averaging down and those who believe the crypto sector is facing a terminal decline.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Constellation Energy Corp

Constellation Energy is experiencing significant volatility as investors weigh the stock's role as a primary nuclear power provider for AI data centers against near-term regulatory concerns and earnings guidance that trailed analyst expectations. While the community remains focused on the structural necessity of nuclear power for scaling AI infrastructure, active discussions are currently split between capitalizing on the stock's recent dip as a long-term value opportunity and hedging against potential grid-related policy risks.

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals is currently capturing investor attention following a strategic deal with Apotex and ongoing clinical momentum for its pipeline drug, ifetroban. The community is actively discussing the stock's tight float, potential squeeze dynamics, and the high-value implications of upcoming ifetroban data for Duchenne muscular dystrophy and oncology indications.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is experiencing intense investor interest as the April 30th PDUFA date for the Auvelity label expansion into Alzheimer's agitation approaches, with analysts increasingly confident in an approval. Community sentiment remains bullish, highlighting the drug's potential as a first-in-class treatment for an underserved market and viewing recent stock volatility as a buying opportunity ahead of anticipated regulatory success and upcoming earnings.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Seagate Technology is trending due to robust demand for high-capacity storage, with investors closely watching its industry-leading positioning in AI data center infrastructure. The community is actively debating the sustainability of the current rally, weighing impressive quarterly results and upward price target revisions against concerns regarding valuation and long-term supply chain capacity.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending as investors debate its dual identity as both a digital asset firm and an emerging AI data center play, particularly amidst ongoing scrutiny of its Helios campus. While some community members remain frustrated by the stock's price sensitivity to Bitcoin and a perceived lack of aggressive communication from leadership regarding data center contracts, others are closely tracking upcoming industry conferences for potential catalysts that could unlock value.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is facing intense volatility following a critical security audit that uncovered a long-standing bug in its privacy protocol, sparking a massive sell-off as traders scramble to evaluate the risk of potential counterfeit supply. While developers have already deployed a patch, the community remains deeply polarized between those panic-selling over transparency concerns and others viewing the significant price dip as a rare buying opportunity for a hardened network.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?

Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care

OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.

Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?

Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings through 2027 could shape its next phase.

OCGN's Catalyst Calendar for Trial Data and Filings Through 2028

Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.

Ocugen (OCGN) Upgraded to Buy: Here's Why

Ocugen (OCGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook

Ocugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.

Ocugen, Inc. (NASDAQ:OCGN) Given Average Recommendation of "Moderate Buy" by Brokerages

Ocugen, Inc. (NASDAQ:OCGN - Get Free Report) has been assigned an average rating of 'Moderate Buy' from the five research firms that are presently covering the company, MarketBeat Ratings reports...

Ocugen Q1 Earnings Call Highlights

Ocugen (NASDAQ:OCGN) used its first-quarter 2026 earnings call to highlight progress across its retinal gene therapy pipeline and to outline a strengthened balance sheet following a newly announced...

Ocugen (NASDAQ:OCGN) Issues Earnings Results, Misses Expectations By $0.01 EPS

Ocugen (NASDAQ:OCGN - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18...

Ocugen (NASDAQ:OCGN) Shares Gap Down  on Disappointing Earnings

Ocugen (NASDAQ:OCGN) Shares Gap Down Following Weak Earnings...

This account has been verified as an official OCGN representative.

Verified Account

Ocugen

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.05	--	--	N/A
Q1 '26	-$0.05	-$0.06	-16.67%	MISSED
Q4 '25	-$0.06	-$0.06	-2.65%	MISSED
Q3 '25	-$0.06	-$0.07	-25.00%	MISSED
Q2 '25	-$0.06	-$0.05	10.71%	BEAT

OCGNOcugen Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest OCGN News